Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 6/20 | 0.41 |
| ▸ | CNR1 | P21554 | 5/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PDE6D | O43924 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | DVL1 | O14640 | 1/20 | 0.39 |
| ▸ | DVL3 | Q92997 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13931387 | 0.96 | PTGS2 (0.45) | PTGS2PLA2G2ACNR2PPARGHDAC1 | |
| SCHEMBL13931388 | 0.92 | PPARG (0.42) | PTGS2PLA2G2ACNR2PPARGHDAC1 | |
| SCHEMBL8179587 | 0.86 | PTGS2 (0.50) | PTGS2PLA2G2AKDM4EPPARGHDAC1 | |
| SCHEMBL8174890 | 0.86 | L3MBTL1 (0.46) | PTGS2PLA2G2ACNR1TP53HDAC1 | |
| SCHEMBL8181548 | 0.85 | PPARG (0.40) | PTGS2PLA2G2AKDM4EPDE6DPPARG | |
| SCHEMBL13931396 | 0.82 | PLA2G2A (0.48) | PTGS2PLA2G2AFAAHSMN1; SMN2PPARG | |
| SCHEMBL13931389 | 0.81 | PLA2G2A (0.49) | PTGS2PLA2G2APPARGPTGESALOX5 | |
| SCHEMBL13931386 | 0.81 | PTGS2 (0.46) | PTGS2PLA2G2ARXFP1PTGESALOX5 | |
| SCHEMBL13931390 | 0.79 | PPARG (0.50) | PTGS2PLA2G2APPARG | |
| SCHEMBL8175805 | 0.78 | PTGS2 (0.54) | PTGS2PLA2G2AKDM4ESMN1; SMN2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | PTGS2 2426/4885PLA2G2A 3963/4885CNR2 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.